Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol corticosteroid-sparing in Crohn's Disease
NCT00349752Phase 3Terminated
- Sponsor
- UCB
- Start
- Nov 2006
- Primary completion
- Jul 2009
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 3
01
Overview
A Phase 3 trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Started Nov 2006; status: terminated.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00349752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00349752.